AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28114798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent metoclopramide infusion (10 mg every 6 h)
Number of subjects: 40
Study 28114798 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous metoclopramide infusion (2 mg/h)
Number of subjects: 40
Study 26541435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 or 2.0 mg monthly or as needed
Number of subjects: 1084
Study 24687826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg per day for 10 weeks
Number of subjects: 169
Study 24687826 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg per day (4 weeks on, 2 weeks off, 4 weeks on) for 10 weeks
Number of subjects: 169
Study 24687826 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician preference
Number of subjects: 169
Study 24687826 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL measures
Number of subjects: 169
Study 23294071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (500 mg)
Number of subjects: 60
Study 23294071 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 60
Study 19297565 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening with PSA testing and digital rectal examination
Number of subjects: 76693
Study 19297565 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 76693
Study 17968163 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation (40 Gy plus 5-FU)
Number of subjects: 218
Study 17968163 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further adjuvant treatment)
Number of subjects: 218
Study 15573278 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 361
Study 15573278 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 361
Study 15573278 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 361
Study 15573278 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedures
Number of subjects: 361
Study 15573278 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary interventions
Number of subjects: 361
Study 11770837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate
Number of subjects: 30
Study 11770837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 30
Study 11770837 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 9670578 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (Amoxycillin, Clarithromycin, Omeprazole) for 6 days
Number of subjects: 88
Study 9670578 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (Omeprazole) for 6 weeks
Number of subjects: 88
Study 9670578 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (Omeprazole)
Number of subjects: 88
Study 10147193 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite alcohol program
Number of subjects: 268
Study 10147193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nutrition) program
Number of subjects: 268
Study 10147193 — intervention group
Group type: COMPARATOR
Intervention: No program
Number of subjects: 268
Study 2452456 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g GVG per day for 3 months
Number of subjects: 78
Study 2452456 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g GVG per day for 3 months
Number of subjects: 78
Study 2452456 — intervention group
Group type: EXPERIMENTAL
Intervention: GVG treatment
Number of subjects: 78
Study 31913927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine
Number of subjects: 127
Study 31913927 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 127
Study 31373737 — intervention group
Group type: EXPERIMENTAL
Intervention: Earthworms + duckweed (group M)
Number of subjects: 270
Study 31373737 — intervention group
Group type: EXPERIMENTAL
Intervention: Duckweed (group P)
Number of subjects: 270
Study 31373737 — intervention group
Group type: COMPARATOR
Intervention: Earthworms (group A)
Number of subjects: 270
Study 28125907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutreal (ready-to-use therapeutic food)
Number of subjects: 112
Study 28125907 — intervention group
Group type: COMPARATOR
Intervention: Defined food (homemade diet)
Number of subjects: 112
Study 28125907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutreal
Number of subjects: 112
Study 28125907 — intervention group
Group type: COMPARATOR
Intervention: Defined food
Number of subjects: 112
Study 25843270 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 1977
Study 25843270 — intervention group
Group type: COMPARATOR
Intervention: Licensed inactivated trivalent influenza vaccine (IIV3)
Number of subjects: 1977
Study 23648616 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered viewing condition
Number of subjects: 10
Study 23648616 — intervention group
Group type: COMPARATOR
Intervention: Uncovered viewing condition (dominant hand)
Number of subjects: 10
Study 23648616 — intervention group
Group type: COMPARATOR
Intervention: Uncovered viewing condition (non-dominant hand)
Number of subjects: 10
Study 21059888 — intervention group
Group type: EXPERIMENTAL
Intervention: Apratastat (oral administration, single or multiple doses, twice daily)
Number of subjects: 3
Study 19350334 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire completed twice a week for test-retest reliability (Group 1)
Number of subjects: 142
Study 19350334 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire with additional tests for validity (Group 2)
Number of subjects: 142
Study 17237688 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled delivery system (Wand)
Number of subjects: 30
Study 17237688 — intervention group
Group type: COMPARATOR
Intervention: Traditional manual syringe technique
Number of subjects: 30
Study 15162250 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour and power Doppler sonography
Number of subjects: 20
Study 15162250 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of blood flow within the tendon
Number of subjects: 20
Study 10693564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet application (Group I)
Number of subjects: 20
Study 10693564 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet application (Group II)
Number of subjects: 20
Study 9408669 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse intervention
Number of subjects: 45
Study 9408669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specialist nurse intervention)
Number of subjects: 45
Study 7902637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.04 mg.kg‐1)
Number of subjects: 20
Study 7902637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.2 mg.kg‐1)
Number of subjects: 20
Study 7902637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 20
Study 7902637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 20
Study 3026106 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237 vaccine alone
Number of subjects: 160
Study 3026106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of polio and RIT 4237 vaccines
Number of subjects: 160
Study 3026106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 3026106 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliovirus vaccine
Number of subjects: 160
Study 31724083 — intervention group
Group type: EXPERIMENTAL
Intervention: Açai pulp (AP)
Number of subjects: 10
Study 31724083 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 29482338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis C-3102
Number of subjects: 0
Study 27226338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<130 mmHg or lower)
Number of subjects: 0
Study 27226338 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure target (<140 mmHg)
Number of subjects: 0
Study 24950747 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK561679 (350 mg nightly for six weeks)
Number of subjects: 0
Study 24950747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for six weeks)
Number of subjects: 0
Study 24950747 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK561679
Number of subjects: 0
Study 24950747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21885963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 60
Study 21885963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18277183 — intervention group
Group type: EXPERIMENTAL
Intervention: Down syndrome participants (DS)
Number of subjects: 13
Study 16182706 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution
Number of subjects: 50
Study 16182706 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 50
Study 12867606 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-impermeable bed covers (active-intervention group)
Number of subjects: 1122
Study 12867606 — intervention group
Group type: COMPARATOR
Intervention: Non-impermeable bed covers (control group)
Number of subjects: 1122
Study 10859040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel (800 mg loading dose followed by 200 mg every 12 h for five doses)
Number of subjects: 1804
Study 10859040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1804
Study 10859040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel
Number of subjects: 1804
Study 8817985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikkiso pump
Number of subjects: 20
Study 8817985 — intervention group
Group type: COMPARATOR
Intervention: BioMedicus pump
Number of subjects: 20
Study 1397742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole, 40 mg i.v. bolus twice daily for up to 5 days
Number of subjects: 39
Study 1397742 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of ranitidine, 400 mg daily for the same time period
Number of subjects: 39
Study 1397742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole, 40 mg twice daily
Number of subjects: 39
Study 1397742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole, 40 mg three times daily
Number of subjects: 39
Study 4010475 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 gm choline and 0.35 mg scopolamine (Ch‐Sc)
Number of subjects: 10
Study 4010475 — intervention group
Group type: COMPARATOR
Intervention: Placebo and scopolamine (Pl‐Sc)
Number of subjects: 10
Study 4010475 — intervention group
Group type: COMPARATOR
Intervention: Placebo and placebo (Pl‐Pl)
Number of subjects: 10
Study 30395147 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating as Treatment (EAT)
Number of subjects: 307
Study 30395147 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (Control)
Number of subjects: 307
Study 28682933 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (12 mg)
Number of subjects: 10
Study 28682933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25758100 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 implant placement
Number of subjects: 38
Study 25758100 — intervention group
Group type: COMPARATOR
Intervention: Type 2 implant placement
Number of subjects: 38
Study 25758100 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Type 1 and Type 2 implant placements
Number of subjects: 38
Study 24113508 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-oriented self-learning and review
Number of subjects: 185
Study 24113508 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional lecture-based teaching)
Number of subjects: 185
Study 22857850 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 2191
Study 22857850 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 2191
Study 20412501 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopically guided caudal epidural steroid, local anesthetic, and hypertonic saline (group 1)
Number of subjects: 38
Study 20412501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided caudal epidural steroid, hypertonic saline, local anesthetic, and hyaluronidase (group 2)
Number of subjects: 38
Study 18157412 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion
Number of subjects: 24
Study 18157412 — intervention group
Group type: COMPARATOR
Intervention: Control (subcutaneous insulin)
Number of subjects: 24
Study 15638906 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 1385
Study 15638906 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 1385
Study 15638906 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 1385
Study 15638906 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 1385
Study 15638906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1385
Study 11331631 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate withdrawal of the catheter after embryo deposit (n = 51)
Number of subjects: 100
Study 11331631 — intervention group
Group type: COMPARATOR
Intervention: 30 seconds delay before catheter withdrawal (n = 49)
Number of subjects: 100
Study 9042093 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate beer consumption (330 mL/day, 20 g of alcohol) for 30 days
Number of subjects: 28
Study 9042093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol consumption)
Number of subjects: 28
Study 7894522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 46
Study 7894522 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA
Number of subjects: 46
Study 7894522 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA in combination with waist-to-hip ratios
Number of subjects: 46
Study 2468891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28
Study 2468891 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 28
Study 2318615 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Diary I (HDI)
Number of subjects: 76
Study 2318615 — intervention group
Group type: COMPARATOR
Intervention: Health Diary II (HDII)
Number of subjects: 76
Study 1002750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate
Number of subjects: 153
Study 1002750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 30711247 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 0
Study 30711247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 27534402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection followed by 12‐h infusion (IV‐IV)
Number of subjects: 99
Study 27534402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus injection followed by intravenous infusion (IC‐IV)
Number of subjects: 99
Study 27534402 — intervention group
Group type: EXPERIMENTAL
Intervention: Only intracoronary bolus injection (IC)
Number of subjects: 99
Study 27313412 — intervention group
Group type: COMPARATOR
Intervention: TC 150 mg
Number of subjects: 30
Study 27313412 — intervention group
Group type: COMPARATOR
Intervention: TC 300 mg
Number of subjects: 30
Study 27313412 — intervention group
Group type: COMPARATOR
Intervention: TC 150 mg and TC 300 mg
Number of subjects: 30
Study 23972413 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-instruction and additional CBT
Number of subjects: 169
Study 23972413 — intervention group
Group type: COMPARATOR
Intervention: Waiting period followed by regular CBT
Number of subjects: 169
Study 21289531 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hep B‐PRP‐T (Group 1)
Number of subjects: 715
Study 21289531 — intervention group
Group type: COMPARATOR
Intervention: DTwP‐Hib, hepatitis B, and OPV vaccines (Group 2)
Number of subjects: 715
Study 21289531 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hep B‐PRP‐T with hepatitis B vaccine at birth (Group 3)
Number of subjects: 715
Study 19814699 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg, once daily for 6 weeks
Number of subjects: 52
Study 19814699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg, once daily for 6 weeks
Number of subjects: 52
Study 19814699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17057415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 10
Study 17057415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg (subgroup of 6 volunteers)
Number of subjects: 10
Study 17057415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15111618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) with cyclophosphamide 1500 mg/m(2), thiotepa 150 mg/m(2), and mitoxantrone 10 mg/m(2) for 4 consecutive days followed by stem-cell support
Number of subjects: 307
Study 15111618 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SD-CT) with cyclophosphamide 500 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) in three cycles
Number of subjects: 307
Study 15111618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT)
Number of subjects: 307
Study 15111618 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SD-CT)
Number of subjects: 307
Study 11692096 — intervention group
Group type: EXPERIMENTAL
Intervention: R-albuterol (6.25-1600 microg)
Number of subjects: 20
Study 11692096 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-albuterol (12.5-3200 microg)
Number of subjects: 20
Study 11692096 — intervention group
Group type: COMPARATOR
Intervention: S-albuterol (6.25-1600 microg)
Number of subjects: 20
Study 11692096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9204651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clodronate (600 mg or 1500 mg in 500 mL of normal saline)
Number of subjects: 60
Study 9204651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clodronate
Number of subjects: 60
Study 9204651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mL of saline)
Number of subjects: 60
Study 9204651 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded choice of agent for pain improvement
Number of subjects: 60
Study 9204651 — intervention group
Group type: COMPARATOR
Intervention: Investigators' blinded selection
Number of subjects: 60
Study 7966073 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sessions of supervised group physical therapy for a period of 9 months
Number of subjects: 59
Study 7966073 — intervention group
Group type: COMPARATOR
Intervention: Daily exercises at home
Number of subjects: 59
Study 7966073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scale utilities
Number of subjects: 59
Study 7966073 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gamble utilities
Number of subjects: 59
Study 7966073 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in rating scale utilities
Number of subjects: 59
Study 7966073 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in standard gamble utilities
Number of subjects: 59
Study 3475309 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: professional mechanical tooth‐cleaning, tongue‐scraping, chlorhexidine treatment, and oral hygiene instructions concentrated on the approximal surfaces, treatment given four times with intervals of two days, followed by one single treatment every six months
Number of subjects: 187
Study 3475309 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: same oral hygiene instructions as for Group I, repeated every six months
Number of subjects: 187
Study 3475309 — intervention group
Group type: COMPARATOR
Intervention: Group III: preventive program by local Dental Health Office, based on mechanical plaque control and topical use of fluorides and chlorhexidine
Number of subjects: 187
Study 29660956 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 37
Study 29660956 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 37
Study 29660956 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional training)
Number of subjects: 37
Study 27098717 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary method
Number of subjects: 50
Study 27098717 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 50
Study 27098717 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 50
Study 25641556 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab (subcutaneous or intravenous administration)
Number of subjects: 52
Study 24099368 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 0
Study 24099368 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 20923485 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose (SMBG)-based intervention
Number of subjects: 161
Study 20923485 — intervention group
Group type: COMPARATOR
Intervention: HbA1c-based control group
Number of subjects: 161
Study 18487892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 9
Study 18487892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi-inspired exercise
Number of subjects: 9
Study 18487892 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study 16413229 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational treatment
Number of subjects: 247
Study 16413229 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled professional care
Number of subjects: 247
Study 16413229 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruism
Number of subjects: 247
Study 14616411 — intervention group
Group type: EXPERIMENTAL
Intervention: voriconazole + erythromycin (1 g twice daily on days 8-14)
Number of subjects: 30